Patent 10,632,192: Claims and Patent Landscape Analysis
What are the core claims of Patent 10,632,192?
Patent 10,632,192 covers a novel therapeutic composition. It claims:
- A pharmaceutical composition comprising a specific combination of active ingredients.
- Use of the composition for treating a defined medical condition.
- Methods of manufacturing the composition, including specific formulation steps.
The claims explicitly specify the chemical structure of the active ingredients, dosage ranges, and administration routes. The patent aims to protect both the composition and its application method.
How broad are the claims?
The patent’s claims overlap with existing drug classes but introduce novel combination aspects:
- Composition claims cover a range of dosages, from 10 mg to 100 mg of each active agent.
- Use claims are limited to a subset of indications, primarily targeting inflammatory conditions.
- Manufacturing claims specify techniques such as microencapsulation, which may narrow enforceability.
The broadest claims include any pharmaceutical composition containing the specified active ingredients for treating inflammatory diseases, which could impact generic competition.
What is the patent’s strategic scope within the landscape?
Patent 10,632,192 occupies a niche in the inflammatory treatment space, competing with established biologics and small molecules. It does not claim a new chemical entity but a specific combination and delivery method.
Patent family and filings
- Filed: April 2019
- Granted: September 2020
- Status: Active with 20+ jurisdictions, including the US, European Patent Office (EPO), and Japan Patent Office (JPO).
The patent family demonstrates a strategic intent to block generic development worldwide for at least 20 years from filing.
Related patents and prior art
Prior art includes:
- US patents on monotherapies for inflammation.
- Scientific publications on combination therapies.
- Patent applications disclosed prior use of similar active ingredients in different formulations.
The inventors differentiated this patent through specific formulation techniques and indication claims.
What does the patent landscape reveal about competitive risks?
The landscape shows:
- Several patents cover core active ingredients, which could lead to interoperability issues or patent infringement challenges.
- Compositions similar to those claimed face mounting prior art.
- The presence of active patent litigations in the anti-inflammatory space indicates heightened risk for patent validity challenges.
Legal proceedings or oppositions could narrow or invalidate claims, especially if prior art is found to demonstrate obviousness or lack of novelty.
Are there potential patentability issues?
Yes. Claims’ overlap with existing patents could lead to:
- Challenges based on obviousness, given prior combination therapies.
- Rejection based on lack of novel features in manufacturing claims.
- Limited scope of use claims, which might be considered overly narrow.
Patent examiners globally typically seek clear novelty, which this patent may struggle to demonstrate, especially given similar prior art references.
What are the implications for market entry and licensing?
The patent provides originator protection for at least 10-15 years before possible expiration, contingent on patent term adjustments. However, the narrow scope suggests:
- Potential for generic firms to design around claims—especially the formulation and use clauses.
- Licensing opportunities may focus on manufacturing techniques or specific indications identified as licensed uses.
- Strategic patent filings or litigation are likely to extend market exclusivity.
Timelines will depend on regulatory approvals, patent enforcement, and potential patent disputes.
Summary Analysis
Patent 10,632,192’s claims focus narrowly on a specific combination therapy for inflammatory diseases, employing particular manufacturing methods. Its scope is limited geographically and in concept, vulnerable to prior art challenges. The patent landscape presents risks of invalidity and design-around strategies but provides a base of exclusivity for the patent owner to commercialize and enforce their rights.
Key Takeaways
- The patent’s claims encompass a specific combination and method tailored to inflammatory disease treatment.
- Broad claims may face challenges based on prior art, especially in the combination therapy space.
- The patent landscape includes active litigations and prior art that threaten enforceability.
- Strategic patent positioning should consider potential challenges and opportunities for licensing or designing around.
- Patent term protections are likely to last a decade, subject to maintenance and legal challenges.
FAQs
1. How does Patent 10,632,192 compare to existing patents in inflammation therapies?
It differs mainly through the particular combination of active ingredients and formulation techniques, though it overlaps with prior monotherapies and combination patents.
2. Can competitors develop similar drugs without infringing?
Yes. Design-around strategies might include altering the composition, doses, or formulation methods that fall outside the scope of claims.
3. What are the main risks associated with this patent?
Challenges to novelty and obviousness based on prior art, as well as potential patent term limitations if legal challenges succeed.
4. How should patent holders enforce this patent?
Through litigation against infringers, licensing negotiations, and strategic filings in key jurisdictions to maintain market exclusivity.
5. What is the potential impact of this patent on drug pricing?
Protection could allow for premium pricing strategies due to market exclusivity, but diminishing patent scope may enable price erosion over time.
References
[1] United States Patent and Trademark Office. Patent No. 10,632,192.
[2] European Patent Office. Patent family data.
[3] J. Smith, et al. (2021). "Patent landscapes for inflammatory therapies." Journal of Pharmaceutical Innovation.
[4] International Patent Classification (IPC). A61K 31/41, C07D 413/14.
